Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863723 | 0.85 | THRB (0.46) | APEX1THRBTDP1MTTP | |
| SCHEMBL5863866 | 0.84 | APEX1 (0.40) | APEX1THRBTDP1MTTP | |
| Hydrochloric Acid SCHEMBL6777668 | 0.84 | THRB (0.44) | APEX1THRBTDP1MTTP | |
| SCHEMBL6766827 | 0.83 | P2RX4 (0.35) | — | |
| SCHEMBL7045213 | 0.80 | MTTP (0.39) | APEX1MTTP | |
| SCHEMBL6777664 | 0.79 | PDK2 (0.40) | APEX1THRBTDP1MTTP | |
| SCHEMBL6766694 | 0.78 | APEX1 (0.39) | APEX1MTTP | |
| SCHEMBL5863393 | 0.78 | MTTP (0.47) | MTTP | |
| SCHEMBL5863337 | 0.78 | GLA (0.40) | MTTP | |
| SCHEMBL7595150 | 0.77 | APEX1 (0.37) | APEX1THRBTDP1S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016071849-A1 | PROCESS FOR THE PREPARATION OF LOMITAPIDE | HETERO RESEARCH FOUNDATION (IN) | 2016-05-12 | — | — | WO | disclosed |
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-6818644-B1 | FLUORENE-9-CARBOXYLIC AMIDES; INHIBITORS OF MICROSOMAL TRIGLYSERIDE-TRANSFER PROTEIN (MTP); ANTILIPEMIC AGENTS; ATHEROSCLEROSIS, DIABETES, EATING DISORDERS, AND PANCREATITIS | BOEHRINGER INGELHEIM PHARM GMBH & CO, KG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| CN-1414956-A | Substituted piperazine derivatives as MIP inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | APEX1 3470/4885THRB 1383/4885TDP1 2302/4885 |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | APEX1 4003/4885THRB 1353/4885TDP1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.